Top

Gepubliceerd in:

01-03-2010 | Editorial

Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Auteurs: E. E. van der Wall, H. M. Siebelink, J. J. Bax

Gepubliceerd in: Netherlands Heart Journal | Uitgave 3/2010

Abstract

Cardiac magnetic resonance imaging (CMR) is an accurate and reliable means of evaluating cardiac morphology, ventricular function, and myocardial perfusion, both for the left and the right ventricle thereby covering a whole spectrum of cardiac diseases. 1 CMR is therefore very well suited for identifying and characterising patients with various manifestations of left ventricular hypertrophy (LVH).

vorige artikel Invasive treatment of ACS: early or later on?

volgende artikel Effects of altitude on exercise level and heart rate in patients with coronary artery disease and healthy controls

P.S. Of note, the above-mentioned article by Germans et al. has been selected as e-learning article with the aim to improve general knowledge on hypertrophic cardiomyopathy and to gather accreditation points. We hope the reader will be stimulated to read the article and respond to the online questions. Instructions will be given at the end of the article.

van der Wall EE, Vliegen HW, de Roos A, Bruschke AV. Magnetic resonance imaging in coronary artery disease. Circulation. 1995;92:2723-39.

Smilde TD, Zuurman MW, Hillege HL, et al. Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy. Am J Hypertens. 2007;20:1097-103.

Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete’s heart: A meta-analysis of cardiac structure and function. Circulation. 2001;101:336-44.

Posma JL, van der Wall EE, Blanksma PK, van der Wall E, Lie KI. New diagnostic options in hypertrophic cardiomyopathy. Am Heart J. 1996;132:1031-41.

Knaapen P, Germans T, Camici PG, et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;294:H986-93.

Germans T, van Rossum AC. The use of cardiac magnetic resonance imaging to determine the aetiology of left ventricular disease and cardiomyopathy. Heart. 2008: 94:510-8.

Ten Cate FJ. Cardiomyopathies: a revolution in molecular medicine and cardiac imaging. Neth Heart J. 2009;17:456-7.

van Dockum WG, Kuijer JP, Götte MJ, et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J. 2006;27:2833-9.

Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-4.

10.

Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol. 2007;49:1874-9.

11.

Olimulder MAGM, van Es J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J. 2009;17:481-6.

12.

de Roos A, Matheijssen NA, Doornbos J, et al. Myocardial infarct size after reperfusion therapy: assessment with Gd-DTPA-enhanced MR imaging. Radiology. 1990;176:517-21.

13.

Vliegen HW, Doornbos J, de Roos A, Jukema JW, Bekedam MA, van der Wall EE. Value of fast gradient echo magnetic resonance angiography as an adjunct to coronary arteriography in detecting and confirming the course of clinically significant coronary artery anomalies. Am J Cardiol. 1997;79:773-6.

14.

Hoogendoorn LI, Pattynama PM, Buis B, van der Geest RJ, van der Wall EE, de Roos A. Noninvasive evaluation of aortocoronary bypass grafts with magnetic resonance flow mapping. Am J Cardiol. 1995;75:845-8.

15.

van der Wall EE, van Dijkman PR, de Roos A, et al. Diagnostic significance of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in thrombolytic treatment for acute myocardial infarction: its potential in assessing reperfusion. Br Heart J. 1990;63:12-7.

16.

van Dijkman PR, van der Wall EE, de Roos A, et al. .Acute, subacute, and chronic myocardial infarction: quantitative analysis of gadolinium-enhanced MR images. Radiology. 1991;180:147-51.

17.

van Rugge FP, Boreel JJ, van der Wall EE, et al. Cardiac first-pass and myocardial perfusion in normal subjects assessed by sub-second Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991; 15:959-65.

18.

Nijveldt R, Beek AM, Hirsch A, et al. ‘No-reflow’ after acute myocardial infarction: direct visualisation of microvascular obstruction by gadolinium-enhanced CMR. Neth Heart J. 2008;16:179-81

19.

Germans T, Nijveldt R, Brouwer WP, et al. The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy. Neth Heart J. 2010;18:135-43.

20.

Elliott P, Andersson B, Arbustini E, , et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270-6.

21.

Papavassiliu T, Germans T, Flüchter S, et al. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson. 2009;11:34.

22.

Michels M, Soliman OI, Phefferkorn J, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009;30:2593-8.

23.

Vehmeijer JT, Christiaans I, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J. 2009;17:464-9.

24.

Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-74.

25.

Germans T, Wilde AA, Dijkmans PA, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol. 2006;48:2518-23.

26.

Germans T, Wilde AA, van Echteld CJ, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy. Neth Heart J. 2007;15:161-3.

27.

van Rijsingen IAW, Hermans-van Ast JF, Arens YHJM, et al. Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest double heterozygosity? Neth Heart J. 2009;17:458-63.

28.

Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. .J Am Coll Cardiol. 2008;51: 1022-30.

29.

Bruder O, Schneider S, Nothnagel D, et al. EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. J Am Coll Cardiol. 2009;54:1457-66.

Titel: Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?
Auteurs: E. E. van der Wall
H. M. Siebelink
J. J. Bax
Publicatiedatum: 01-03-2010
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 3/2010
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03091748

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2010

Giant left atrial appendage

Invasive treatment of ACS: early or later on?

Effects of altitude on exercise level and heart rate in patients with coronary artery disease and healthy controls

Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention

Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome

Procedural and long-term outcome of primary percutaneous coronary intervention in octogenarians